A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer

British Journal of Cancer

Volumn 85, Issue 7, 2001, Pages 1064-1069

  Watanabe, Y ^a   Koi, M ^c   Hemmi, H ^b   Hoshai, H ^a   Noda, K ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Acquired resistance; CDDP based chemotherapy; Microsatellite instability; Ovarian cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DNA PRIMERS; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN BIOSYNTHESIS; PROTEINS; PROTO-ONCOGENE PROTEINS;

EID: 0035964610     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6692037     Document Type: Article

References (28)

1. Loss of DNA mismatch repair in acquired resistance to cisplatin
2. Microsatellite instability in ovarian, other pelvic carcinomas
3. Microsatellite instability, apoptosis, loss of p53 function in drug-resistant tumor cells
4. Microsatellite instability differences between familial and sporadic ovarian cancers
5. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
6. Distribution of p53 in human cancer cells alters the response to therapeutic agents
7. Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer
8. Loss of DNA mismatch repair: Effects on the rate of mutation to drug resistance
9. The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6 alkylguanine-DNA-alkyltransferase of human tumour xenografts
10. The role of DNA mismatch repair in acquired resistance to cisplatin
11. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells
12. Microsatellite analysis in serous tumors of the ovary
13. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients
14. Genomic instability and tolerance to alkylating agents
15. Association of 5′ CpG demethylation and altered chromatine structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells
16. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR/P-glycoprotein
17. Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival
18. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
19. Phase III randomized study of cisplatin versus paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
20. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer
21. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A gynecologic oncology group study
22. Update of the NCCN ovarian cancer practice guidelines
23. Genetic alterations distinguish different types of ovarian cancer
24. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
25. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
26. A role of methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
27. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells